Soleus Capital Management, L.P. 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Soleus Capital Management, L.P. disclosed 94 US equity positions worth $1.4bn in its Q2 2025 13F filing. The largest position was KRYS at 8.8% of the reported book, followed by NVCR and TGTX. Against the Q1 2025 filing, it opened 13 new positions, added to 16 and reduced 13 among the top 50 holdings.
What did Soleus Capital Management, L.P. own in Q2 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | KRYS KRYSTAL BIOTECH INC | Healthcare | 8.8% | $126.9m | 922,958 | 109% | added |
| 2 | NVCR NOVOCURE LTD | Healthcare | 8.5% | $122.9m | 6,904,302 | 25% | added |
| 3 | TGTX TG THERAPEUTICS INC | Healthcare | 5.6% | $80.8m | 2,243,935 | -21% | reduced |
| 4 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 4.2% | $60.3m | 209,794 | 35% | added |
| 5 | BBNX BETA BIONICS INC | Healthcare | 3.8% | $55.6m | 3,820,158 | 13% | added |
| 6 | GRFS GRIFOLS S A | Healthcare | 3.6% | $52.0m | 5,756,805 | -19% | reduced |
| 7 | STAA STAAR SURGICAL CO | Healthcare | 3.5% | $50.1m | 2,984,733 | 16% | added |
| 8 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 3.4% | $49.6m | 902,304 | -16% | reduced |
| 9 | ORGO ORGANOGENESIS HLDGS INC | Healthcare | 3.1% | $45.2m | 12,343,351 | -1% | reduced |
| 10 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.8% | $40.7m | 966,740 | -15% | reduced |
| 11 | CELC CELCUITY INC | Healthcare | 2.8% | $40.2m | 3,011,818 | 17% | added |
| 12 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.4% | $34.8m | 106,750 | – | new |
| 13 | 430 TERNS PHARMACEUTICALS INC | 2.1% | $30.5m | 8,167,100 | 0% | held | |
| 14 | URGN UROGEN PHARMA LTD | Healthcare | 2.1% | $29.9m | 2,185,000 | – | new |
| 15 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.9% | $27.6m | 2,422,833 | 0% | held |
| 16 | ELV ELEVANCE HEALTH INC | Healthcare | 1.9% | $27.2m | 70,000 | – | new |
| 17 | UNH UNITEDHEALTH GROUP INC | Healthcare | 1.9% | $26.9m | 86,250 | – | new |
| 18 | NPCE NEUROPACE INC | 1.8% | $25.8m | 2,312,957 | -11% | reduced | |
| 19 | ARGX ARGENX SE | Healthcare | 1.6% | $23.6m | 42,876 | 48% | added |
| 20 | SU6 SURMODICS INC | 1.6% | $23.4m | 789,060 | 0% | held | |
| 21 | GERN GERON CORP | Healthcare | 1.6% | $22.8m | 16,140,000 | 572% | added |
| 22 | CDTX CIDARA THERAPEUTICS INC | 1.6% | $22.5m | 462,811 | – | new | |
| 23 | EOLS EVOLUS INC | Healthcare | 1.3% | $19.5m | 2,119,000 | 96% | added |
| 24 | HUM HUMANA INC | Healthcare | 1.3% | $19.5m | 79,600 | – | new |
| 25 | VCYT VERACYTE INC | Healthcare | 1.3% | $19.3m | 715,439 | – | new |
| 26 | IART INTEGRA LIFESCIENCES HLDGS C | Healthcare | 1.2% | $17.0m | 1,387,818 | 29% | added |
| 27 | AXGN AXOGEN INC | Healthcare | 1.1% | $15.8m | 1,459,395 | 1% | added |
| 28 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 1.0% | $15.2m | 298,696 | – | new |
| 29 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.0% | $14.7m | 85,000 | 51% | added |
| 30 | INSP INSPIRE MED SYS INC | Healthcare | 1.0% | $14.1m | 109,000 | 179% | added |
| 31 | TWST TWIST BIOSCIENCE CORP | Healthcare | 0.9% | $13.0m | 354,401 | – | new |
| 32 | PHVS PHARVARIS N V | 0.9% | $12.9m | 732,968 | -10% | reduced | |
| 33 | IKT INHIBIKASE THERAPEUTICS INC | 0.9% | $12.3m | 6,325,000 | 0% | held | |
| 34 | RIGL RIGEL PHARMACEUTICALS INC | 0.9% | $12.3m | 658,145 | -42% | reduced | |
| 35 | EDAP TMS S A | 0.8% | $12.1m | 7,309,254 | 0% | held | |
| 36 | THERATECHNOLOGIES INC | 0.8% | $11.3m | 4,801,376 | 0% | held | |
| 37 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.7% | $10.2m | 1,092,110 | 34% | added |
| 38 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.7% | $10.0m | 6,978,942 | 0% | held |
| 39 | ENOV ENOVIS CORPORATION | Healthcare | 0.7% | $9.9m | 315,000 | – | new |
| 40 | NUVALENT INC | 0.7% | $9.5m | 125,000 | -42% | reduced | |
| 41 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 0.6% | $9.1m | 211,900 | – | new |
| 42 | JSPR JASPER THERAPEUTICS INC | 0.6% | $8.3m | 1,494,420 | 0% | held | |
| 43 | ACLXGBX ARCELLX INC | 0.6% | $8.1m | 123,031 | -20% | reduced | |
| 44 | JBIO JADE BIOSCIENCES INC | 0.5% | $8.0m | 796,744 | – | new | |
| 45 | INSM INSMED INC | Healthcare | 0.5% | $7.3m | 72,772 | -73% | reduced |
| 46 | ANAB ANAPTYSBIO INC | Healthcare | 0.5% | $7.1m | 321,040 | 215% | added |
| 47 | KINIKSA PHARMACEUTICALS INTL | 0.5% | $7.0m | 254,689 | -46% | reduced | |
| 48 | SION SIONNA THERAPEUTICS INC | 0.5% | $6.5m | 376,000 | 57% | added | |
| 49 | CBIO CRESCENT BIOPHARMA INC. | 0.4% | $6.5m | 400,000 | – | new | |
| 50 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.4% | $5.6m | 3,261,707 | -58% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.